ProteoGenix, ʻO Bio-Rad a me Miltenyi Biotec i ka hoʻolako ʻana i ka protein maʻamau: Pehea e loiloi ai i nā mea hoʻolako peptide maʻamau

Pane wikiwiki

Hōʻike ka mākeke recombinant-proteins i kapa ʻia ʻo Bio-Rad Laboratories, ʻO Miltenyi Biotec a me ProteoGenix ma waena o nā mea komo o ka ʻāpana e wehewehe i nā hui com…

No ke aha ʻo ka laulā papa inoa he proxy nāwaliwali no ka hiki ke hāʻawi peptide maʻamau

ʻelua ʻaoʻao lawelawe hoʻolako, kekahi e hōʻike ana i kahi papa helu o nā cytokines recombinant a me nā kumu ulu, ʻo kekahi

ʻO nā protein recombinant vs peptide synthesis market ʻO nā protein recombinant vs peptide synthesis market, e like me ka manao mai ke kumu i oleloia. ʻO nā protein recombinant vs peptide synthesis market. ʻikepili pā hui: 2025: ʻO nā protein recombinant 3.4, ʻO ka hoʻohuihui peptide 0; 2026: ʻO nā protein recombinant 3.9, ʻO ka hoʻohuihui peptide 0; 2033: ʻO nā protein recombinant 6.6, ʻO ka hoʻohuihui peptide 1.8406; 2024: ʻO nā protein recombinant 0, ʻO ka peptide synthesis 0.9614.Source: Nā hōʻike mākeke Grand View Research 2026. ʻO nā protein recombinant vs peptide synthesis market 0 2.5 5 7.5 10 ʻO nā protein recombinant ʻO ka hoʻohuihui peptide 3.4 0 2025 3.9 0 2026 6.6 1.8406 2033 0 0.9614 2024 Puna: Nā hōʻike mākeke Grand View Research (2026)

ʻAʻole ʻōlelo ka papa helu nui e pili ana inā hiki i ka mea hoʻolako ke holo i kahi kaʻina āu e hoʻouna ai iā lākou. Hoʻokomo ʻo Grand View Research i ka mākeke protein recombinant ma USD 3.4 piliona ma 2025, USD 3.9 piliona ma 2026 a me USD 6.6 piliona e 2033 ma 8.0% CAGR, ʻoiai ke wānana nei ka mākeke synthesis peptide e hōʻea i ka USD 1,840.6 miliona e 2033 mai USD 961.4 miliona iloko 2024 ma 7.8% CAGR (Noi Nui, 2026; Noi Nui, 2026). Ana nā wānana ʻelua i nā mea like ʻole, a uhi ka helu peptide i ka mākeke peptide-synthesis holoʻokoʻa, ʻaʻole hoʻokahi synthesis maʻamau.

Hoʻokaʻawale ka papa inoa o ka mea komo ma ke ʻano kūpono no ka mea kūʻai aku. Nā Proteina Bio-Rad & Hoʻonohonoho ʻia ka papa inoa peptides a puni nā cytokines, hormones, nā kumu ulu a me nā chemokines i hoʻolako ʻia ma ke ʻano he recombinant, i hoʻomaʻemaʻe ʻia a i ʻole HRP i hoʻopili ʻia, a ʻo ka lawelawe maʻamau i wehewehe ʻia he hana antibody maʻamau, ʻaʻole hana peptide maʻamau (Bio-Rad, kiʻi ʻia 2026). Kūkulu ʻia ka waihona i hoʻopuka ʻia e Miltenyi Biotec a puni ka biopharma a me ka hana cell-therapy ma mua o kahi kahua peptide maʻamau i kākau ʻia. (Miltenyi Biotec, kiʻi ʻia 2026). ʻAʻohe ʻōlelo he koi e pili ana i ka mea e hiki ai i kēlā mau ʻoihana ke hana; he olelo e pili ana i na mea a lakou e hoolaha nei.

ProteoGenix, ʻO Bio-Rad a me Miltenyi Biotec i ka hoʻolako ʻana i ka protein maʻamau: Pehea e loiloi ai i nā mea hoʻolako peptide maʻamau

ʻO ka ʻaoʻao lawelawe ponoʻī a kahi mea hoʻolako ʻoi aku ka maikaʻi o ka proxy. Hoʻopuka ʻo ProteoGenix i ka peptide synthesis maʻamau ma mua o 150 nā ʻakika amino, mai $2.12 no ka waikawa amino me ka uku haʻahaʻa o € 69 no ka peptide, ka maʻemaʻe mai ka crude i ≥98%, lawe mai 10 nā lā ʻoihana, a me MS me HPLC profiles ma ka hōʻike QC maʻamau (ProteoGenix, kiʻi ʻia 2026). ʻO ia kahi paʻa mole-level e hiki i ka mea kūʻai ke hoʻāʻo e kūʻē i kahi ʻōlelo. ʻAʻole ka nui o ka puke.

He aha ke ʻano o ka hohonu o ka hoʻoponopono ʻana no kahi mea hoʻolako peptide - kaʻina, kūkulu a me ke ala?

ʻO ka hohonu o ka hoʻopilikino ke koena laula, hana i nā ʻano a me nā ala synthesis e hana ai ka mea hoʻolako ma ke kākau ʻana, me ka nui o ka paa ana o ia mau hoohiki. ʻO kahi hoʻohālikelike pololei recombinant-versus-kemika o kahi peptide waiwai-cysteine ​​e hōʻike ana i ka nui o ke ala e hoʻololi ai i ka pane.: ka 39-koena spider toxin Ba1 i hanaia ma 11 mg no 0.1 mmol o ka hui ʻana o ka waikawa amino e ka hoʻohui kemika, kū'ē i nā hua hou o 100 μg/L a 900 μg/L o ka moʻomeheu no nā mea hana ʻelua i hoʻopaʻa inoa ʻia, ka mea i lawe 247 a 77 koena pakahi (Clement et al., 2015). ʻO ke kūkulu ʻana o ke ala recombinant ma luna o kahi ʻāpana o ka hoʻohālikelike, ʻaʻole he footnote.

E hahai ana ke koho ala i ka pale ma mua o ka lula hoʻokahi. ʻOi ʻia ka synthesis kemika no ka maʻamau 5 i 40 a i ʻole 50 koena, no nā koena kūlohelohe ʻole e like me D-amino acids, β-amino acids a me N-methyl a i ʻole nā ​​lepili isotopic, no nā hoʻololi synthetic a me nā wahi kikoʻī, a no nā manawa pōkole; ʻoi aku ka maikaʻi o ka ʻōlelo recombinant ma luna 40 i 50 koena, no nā kaʻina hoʻopaʻa genetically, no nā hoʻololi biosynthetic e like me ka glycosylation ke hoʻopuka ka mea hoʻokipa i ke ʻano kūpono, a no nā hale hana multi-disulfide lōʻihi, ʻoiai hiki i ka mea hoʻokipa ke kuhi hewa i ka huahana a pono e hōʻoia ʻia (Clement et al., 2015, 2015). SPPS o nā peptides o ka liʻiliʻi ma mua o 50 ʻO nā koena e ka Fmoc chemistry he "maʻamau", ʻoiai ka synthesis kemika o nā peptides lōʻihi ma luna 50 paʻakikī nā amino acids, ʻoi aku ka nui ma ka hana nui (ʻO Wang et al., 2022).

Palena

ʻO ka hoʻohui ʻana i nā kemika

ʻŌlelo hoʻohui hou

Laulā koena

me ka pili 5 i 40/50

ma luna aʻe 40 i 50

ʻO nā koena kūlohelohe ʻole

makemake ʻia

kaupalena i ka genetically encoded

Hoʻololi

synthetic, kikoʻī pūnaewele

biosynthetic, hilinaʻi hoʻokipa

Ke kaumaha disulfide

pono ke anuu pelu

Hale Hana Hana Peptide Synthesis hana lōʻihi multi-disulfide

Intavis Peptide Synthesizer Laina manawa

sh Kaiser Mea Hoʻolako Mea Mea Hana Peptide E ho'āʻo i ka peptide Synthesis ort

lōʻihi, hilinaʻi-kūkulu

E noi i ka lōʻihi loa a me ke ala i kapa ʻia ma ka ʻōlelo. ʻO kahi helu i hōʻike ʻia ma kahi ʻaoʻao lawelawe a me kahi helu a ka mea hoʻolako e hōʻoiaʻiʻo i kāu kaʻina he mau ʻokoʻa like ʻole, a ʻo ka mea mua ka mea hiki iā ʻoe ke nānā ma mua o ke kauoha ʻana.

He aha ka ʻike hoʻololi e pono iaʻu e hōʻoia ma mua o ka hāʻawi ʻana i kahi papahana?

he chromatogram HPLC hoʻohuli ʻia o kahi synthesis peptide i hoʻololi ʻia me ka piko nui., ka holoi ʻana a me ka ʻoki ʻana

Hiki ke hōʻoia ʻia ka ʻike hoʻololi ma o ka papa inoa inoa a me nā hōʻike mai kahi papahana mua ma ka papa kemika like. Hāʻule ka peptide kikoʻī kikoʻī a me ka hoʻololi ʻana i ka protein i ʻehā mau ʻāpana: ka hoʻohana ʻana i nā ʻokoʻa like ʻole i nā wahi kemika ma ka N-terminus, C-terminus a i ʻole nā ​​koena o loko; hōʻailona-a-hoʻololi; hoʻololi kemika pili kokoke; a me nā hoʻolālā enzymatic (ʻO Duan et al., 2026). Pono ka mea hoʻolako e koi ana i ka hiki ke hoʻololi ākea ke kau i kāu kemika i noi ʻia ma kekahi o ia mau ʻāpana a inoa i ke ala e hoʻohana ai..

ʻOi aku ka mea nui o ke ʻano hōʻoia ma mua o ka papa inoa. E noi i kahi papahana mua ma ka papa like, ke ala i hoʻohana ʻia, ʻO ke ʻano maʻamau ma mua o ka hoʻomaʻemaʻe ʻana, a inā i ola ka hoʻololi ʻana i ka cleavage a me ka deprotection. A 2026 Nature Chemistry study of 539 ua kānana ʻia nā ʻakika amino non-canonical no ka mea wale nō 49 ua loaʻa ia mau kaʻina no ke aʻo ʻana, He palena pololei ia i ka lōʻihi o ka hiki ʻana o nā mea hana wānana i nā peptides i hoʻololi ʻia (ʻO Tamás et al., 2026). ʻAʻohe kumu o kēia pūʻulu e kākoʻo ana i ka hoʻopili ʻana i ka wānana hōʻuluʻulu i nā peptides i loaʻa nā amino amino non-canonical., no laila, pono e mālama ʻia ka ʻōlelo a ka mea hoʻolako e wānana i ke ʻano no kahi kaʻina i hoʻololi ʻia me he mea lā ʻaʻole i hōʻoia ʻia. Peptide Nui

He papa inoa noi hana: ka inoa hoʻololi a me ke kemika i hoʻohana ʻia; ka papahana hui pale; ka ʻike ʻana o ka HPLC ma mua o ka hoʻomaʻemaʻe ʻana; ʻo ke kiko kikoʻī e hōʻoia ana i ka neʻe nui o ka hoʻololi; a me ka hua o ka huahana i hoʻololi ʻia ma hope o ka ʻoki ʻana. Inā ʻaʻole hiki i ka mea hoʻolako ke hoʻopuka i ka ʻōpala pala, ʻo ke koi hoʻololi e kau ʻia ma ka hopena hoʻomaʻemaʻe wale nō, ka mea huna i ka synthesis.

He aha ka mea i loko o kahi pūʻolo ʻikepili analytical kikoʻī, a he aha nā kūlana e hoʻoponopono ai?

ʻO kahi CoA kikoʻī he moʻolelo o nā hoʻokolohua ma kahi ʻāpana i wehewehe ʻia, a me kona mau kahua ʻike i ka inoa peptide, i loko a i ʻole ka helu helu, ʻO ke kaʻina N-to-C piha me nā hoʻololi hope a me ka pilina disulfide, molecular formula a me ka awelika a i ʻole ka monoisotopic mass, ʻano hoʻohālikelike e like me TFA, acetate a chloride paha, nui ka helu e pili ana i ka vial, ka mooolelo synthesis, chromatogram, nuipa a me ka hoʻoholo hoʻokuʻu, me ka hana ʻana, ka nānā ʻana a me nā lā hoʻokuʻu a me ke ʻano kino (PeptidesInfo, 2026). ʻO ka helu hailona ka heleuma. ʻAʻole wehewehe ke kaʻina me ka hoʻololi ʻole ʻana a i ʻole ke ʻano counterion i ka mea. Hale Hana Mea Hana Peptide

Pono e lawe i kēlā me kēia lālani hopena analytical i ke ʻano i hoʻāʻo ʻia, ʻano ID a me ka mana, kikoʻī a i ʻole ka ʻae ʻana, ana i ka hopena me na wae, hoʻomākaukau laʻana, mea hoʻomaopopo, mea nānā a loiloi, he ʻōlelo ʻae a hāʻule paha, a me kahi loulou i ka chromatogram a i ʻole ke kikoo lehulehu, me nā loina MHRA ALCOA+ (hiki ke pili, hiki ke heluhelu, hoʻokahi manawa, kumu, pololei) e like me ka manao e pili ana (PeptidesInfo, 2026). I Q2(R2) a me Q14, paʻi ʻia e like me nā alakaʻi hope FDA ma 7 Malaki 2024 i loko 89 FR 16582, e wehewehe i nā ʻāpana hōʻoia e pono e hoʻoponopono i kahi ala pale: pololei, pololei, kikoʻī, palena ʻike, palena quantitation, laina laina, ka laulā a me ka ikaika, a me Q2(R2) uhi ʻia ka hoʻohana ʻana i ka ʻikepili spectroscopic (Kakau Federal, 2024). ʻO kahi ID kumu ʻaʻole i palapala ʻāina i kēlā mau hiʻohiʻona he lepili, ʻaʻole he ala.

Māhele 11 pili ka laulā i nā moʻolelo i hoʻoponopono ʻia a me nā lula predicate e pili ana. ʻAʻole hoʻokuʻu ke kulekele hoʻokō a FDA i nā koi predicate a i ʻole ʻāpana āpau 11 nā mana. E hōʻoia i nā mea a me nā mana e pili ana i ka ʻōnaehana i manaʻo ʻia a hoʻohana.

He aha ka hana inā hāʻule ka ala synthesis mua, a pehea e loiloi ʻia ai ke kākoʻo noiʻi?

he kumulāʻau hoʻoholo e hoʻomaka ana mai kahi ʻaoʻao HPLC kino ʻole i hoʻoholo ʻia, lālā i diagnose-mai-crude, a laila e resin a

ʻO ka haʻawina hoʻohui i ʻōlelo ʻia e pili ana i kahi ʻikepili synthesis i koho ʻia. Kona kokoke 49.9% ʻAʻole ʻo ka helu hōʻuluʻulu he helu hemahema ʻoihana, a ʻaʻole ia e hōʻike ana he mea nui ʻole ke koena kauoha. Kaʻina, kemika, ʻO ke kaʻina hana a me nā kūlana hoʻokolohua e pili ana i ka hiki ke ala.

E noiʻi i ka ʻikepili analytical maʻemaʻe ma mua o ka hana hou ʻana i kahi synthesis i hāʻule ʻole. Hiki i nā koho ke komo i ka hoʻouka resin, mea hoʻoheheʻe, kemika hui, pale iwi kuamoʻo a hui ʻāpana. Hōʻike nā hiʻohiʻona pseudoproline i hōʻike ʻia i nā loli kikoʻī; e wehewehe ana i ka piʻi ʻana mai 17% i 75% e like me 58 pale nā ​​helu pākēneka i ka huikau ʻana i ka hoʻomaikaʻi ʻana a me ka pili.

E loiloi i ke kākoʻo noiʻi kūʻē i kēlā lāʻau. E nīnau i ka lālā e lawe ai ka mea hoʻolako i kāu kaʻina a no ke aha, inā hoʻopiʻi ʻia ka re-synthesis, a ʻo wai ka mea heluhelu i ke ʻano o ke ʻano. ʻO kahi mea hāʻawi e pane me ka inoa protocol ma mua o kahi hōʻailona ʻaʻole i komo i ke kaʻina.

He aha ke kānāwai hoʻoholo e hoʻopili ai ka mea kūʻai aku i ka loiloi mea hoʻolako?

E hoʻopili i kahi lula ʻelua ʻāpana: e hōʻoia i nā pae hoʻohālike ʻehā mai ka palapala ma mua o ka ʻōlelo, a laila koi i ka pane hāʻule ma ke kākau ʻana ma mua o ke kauoha kūʻai. Hoʻololi ke koho mea hoʻolako peptide synthesis maʻamau i nā palapala hoʻohiki, ʻaʻole ma ka nui o ka papa inoa a i ʻole ma ka papa inoa o nā mea komo.

Kuhi ʻia nā manawa alakaʻi e ka pālākiō synthesis Kuhi ʻia nā manawa alakaʻi e ka pālākiō synthesis: nā waiwai no ka noiʻi ʻana o Milligram, Gram / pailaka ole GMP, Kilogram / GMP-API. Kuhi ʻia nā manawa alakaʻi e ka pālākiō synthesis. ʻikepili pae pae: ʻImi miligram 4; Gram / pailaka ole GMP 4; Kilogram / GMP-API 26. Puna: Pangu Peptide synthesis scale chart 2026-09-22. Kuhi ʻia nā manawa alakaʻi e ka pālākiō synthesis Miligramnoiʻi 4 Gram / pailakaʻaʻole GMP 4 Kilogram /GMP-API 26 Puna: Pangu Peptide synthesis scale chart (2026-09-22)

Hoʻopili ka nānā palapala i ka lōʻihi a me ke ala, ka papa inoa hoʻololi me kahi papahana mua ma ka papa like, he laʻana CoA kikoʻī kikoʻī me nā ID kaʻina a me nā meheu maka, a me kahi mea hoʻopili loea i kapa ʻia nāna e heluhelu i ka ʻikepili maʻemaʻe. Hoʻopili ka ʻōlelo paʻa i ka mea e hana inā hāʻule ke ala mua. Hāʻawi nā manawa alakaʻi i ʻōlelo ʻia e ka mea kūʻai aku i ka papa hoʻolālā: holo ana ka unahi noiʻi milligram 1 i 4 pule pule, gram a i ʻole hoʻokele hoʻokele non-GMP 2 i 4 pule pule, a me kilo a i ʻole GMP a me ka hana API 3 i 6 mahina (Bank Peptide, ʻaoʻao hou 2026-09-22). ʻO kēia nā puka makani hoʻolaha mai nā mea hoʻolako, ʻaʻole ana i ka hana, no laila e mālama iā lākou e like me nā pae hoʻolālā a hōʻoia iā lākou i ka ʻōlelo.

He ʻokoʻa ka mea hoʻolako peptide noiʻi a me kahi CDMO ma ka lawelawe, ʻōnaehana maikaʻi a me nā hōʻike ma mua o ke kūʻai aku ʻana i nā peptides: a CDMO hoʻohui kaʻina hana, hoʻonui, ʻano hōʻoia, hoʻomalu haumia, palapala hoʻoponopono a me ka hana cGMP ma waena o ka ʻike ʻana i ka lako ʻoihana (Decibio, 2026-05-20). E hoʻoholo i ka mea e pono ai kāu papahana ma mua o ka hoʻohālikelike ʻana i nā huaʻōlelo, no ka mea, pane ʻokoʻa nā nīnau ʻelua.

Nīnau pinepine

Manaʻo paha ka nui o ka mea kūʻai aku i ka hiki ke synthesis maʻamau?

ʻAʻole. Nā Proteina Bio-Rad & Hoʻokumu ʻia ka ʻatikala Peptides a puni ka ʻatikala a me nā huahana workflow, a ʻo kāna lawelawe maʻamau i wehewehe ʻia he hana antibody maʻamau, ʻaʻole hana peptide maʻamau (Bio-Rad, kiʻi ʻia 2026). Hōʻike ʻia ka hiki ma kahi ʻaoʻao lawelawe e hōʻike ana i ke koena laulima, alahele, ka maemae a me ka unahi, e like me kā ProteoGenix i hana me nā mea ʻoi aku 150 nā ʻakika amino, ≥98% ka maemae a me ka lawe ana mai 10 nā lā ʻoihana (ProteoGenix, kiʻi ʻia 2026).

Pehea ka lōʻihi o kahi kauoha peptide maʻamau?

ʻO nā puka makani i ʻōlelo ʻia e nā mea kūʻai aku 1 i 4 nā pule ma ka pālākiō noiʻi milligram, 2 i 4 nā pule no ka hana gram a i ʻole ka hana hoʻokele GMP, a 3 i 6 mahina no ke kilo kilo a i ʻole GMP a me ka paena API (Bank Peptide, hōʻano hou 2026-09-22). ʻO kēia nā pae i hoʻolaha ʻia, ʻaʻole nā ​​hōʻailona, a hiki i kahi kaʻina paʻakikī ke hoʻonui iā lākou.

He aha ka maʻemaʻe aʻu e wehewehe ai?

ʻO nā māka maʻemaʻe o ka mea kūʻai aku a me nā hiʻohiʻona huli ʻana he wehewehe ʻoihana, ʻaʻole nā ​​ʻae ʻae honua. E wehewehe i ka ʻike, pilikia haumia, maʻiʻo, kūpono kūpono a me ka lā hoʻopuka pono no kēia papahana, a e kiʻi i kahi ʻōlelo kuhi no ka hana pololei.

Hiki ke wānana ʻia ka hui ʻana no kaʻu kaʻina?

hapa. ʻO ka hui ʻana o ka amino acid e hoʻoholo nui i ka hui ʻana, a he kumu hoʻohālike i aʻo ʻia 539 wānana nā kaʻina hana i ka makemake o ka hōʻuluʻulu ʻana a hoʻonohonoho i nā mea pani e hōʻemi ai (ʻO Tamás et al., 2026, Malaki 2026). ʻO ka haʻawina like i kānana i nā ʻakika amino non-canonical, no laila, ʻaʻole hiki ke wānana i nā peptides i hoʻololi ʻia.

Ka hopena

Paʻa nā pae hoʻohālike ʻehā i hoʻokahi hoʻokolohua: hohonu hoʻopilikino i nā koena a me ke ala, ʻike loea hoʻololi i hōʻoia ʻia ma kahi papahana mua ma ka papa like, analytical transparency a hiki i ke kaʻina hana ID a me ka maka, a me ke kākoʻo noiʻi e pane ana i kahi synthesis i hāʻule ʻole me kahi hōʻailona ma mua o ka hana hou ʻana. Hōʻike ka ʻāina mākeke i ke kumu o kēia. He hōʻike i kapa ʻia ʻo Bio-Rad, Hōʻike ʻo Miltenyi Biotec a me ProteoGenix i nā mea komo i nā protein recombinant, a ʻo ka mākeke peptide synthesis i kūʻai maoli ʻia e nā mea kūʻai mai ke wānana ʻia a hiki i ka USD 1,840.6 miliona e 2033 (Noi Nui, 2026).

ʻO ka hana aʻe he noi palapala ma mua o kekahi ʻōlelo: he laʻana CoA kikoʻī nui me nā ID kaʻina, he papahana mua i kāu papa hoʻololi, ka lōʻihi o ke kaʻina hana e pono ai ka mea hoʻolako, a me ka mea i kapa ʻia nāna e heluhelu i kāu ʻōlelo ʻino. E nīnau i nā mea e hoʻololi ai ke hāʻule ke ala mua. Hoʻokaʻawale nā ​​pane i kahi mea hoʻolako e hiki ke holo i kāu kaʻina mai kahi mea i papa inoa iā ia.


Mea hoʻopuka: MOL Changes. Hoʻohou 15 ʻOkakopa 2026. Hoʻopili kēia ʻatikala i nā kumu lehulehu i ʻōlelo ʻia a hāʻawi i kahi hoʻolālā hoʻolālā. ʻAʻole ia e hōʻike i kahi loiloi hoʻolako kūʻokoʻa a i ʻole kahi noiʻi hoʻokolohua MOL Changes kumu.

Hōʻike kālepa: Hāʻawi ʻo MOL Changes i nā lawelawe peptide a loaʻa iā ia kahi hoihoi pāʻoihana i kēia kumuhana. Pono e hoʻopaʻa ʻia ka mana o ka papahana a me ka laulā analytical e kūʻē i ka hoʻohana i manaʻo ʻia a me kahi kikoʻī i kākau ʻia.

Xiaoxia Chen

Xiaoxia Chen

Laau Laau Hou R&D ʻenehana Kaʻike kumu: Loaʻa ka pahuhopu, pilina hana-hana (SAR) kālailai, peptide-lāʻau conjugates (Nā PDC), a me ka hoʻomohala ʻana i nā peptides anti-kahiko a me ka metabolic.

Pilikino: Ua alakaʻi ʻo Xiaoxia Chen i ka ʻike mua ʻana a me ka noiʻi preclinical no kekahi mau lāʻau peptide metabolic a me ka tumor-targeted.. ʻAʻole wale ʻo ia i mākaukau i ka nānā ʻana i nā hale waihona puke peptide, akā akamai nō hoʻi i ka hoʻohana ʻana i ka biology computational kōkua AI no ka hoʻolālā ʻana o ka de novo peptide sequence.. I kēia manawa, ke alakaʻi nei ʻo ia i kahi hui i hoʻolaʻa ʻia i ka noiʻi hohonu a me ka hoʻomohala ʻana o nā agonists multifunctional hanauna hou (like me pālua- a i ʻole nā ​​peptides hoʻohaʻahaʻa momona ʻekolu) a me nā peptides hoʻoponopono hou i ke kino.

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana